"A MULTI-COUNTRY, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO DOCUMENT THE SAFETY, TOLERABLITY AND EFFECT OF ALIROCUMAB ON ATHEROGENIC LIPOPROTEINS IN HIGH CARDIO-VASCULAR RISK PATIENTS WITH SEVERE HYPERCHOLESTEROLEMIA NOT ADEQUATELY CONTROLLED WITH CONVENTIONAL LIPID-MODIFYING THERAPIES."

Registry ID

LPS14245

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

SANOFI AVENTIS GROUP

Start date

2015-06-30

Last update

2015-05-13

Conditions

• HYPERCHOLESTEROLEMIA

Related clinical trials

• A PHASE 3, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK-0616 IN ADULTS WITH HYPERCHOLESTEROLEMIA
• A DOUBLE-BLIND, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AMG 145, COMPARED WITH EZETIMIBE, IN HYPERCHOLESTEROLEMIC SUBJECTS UNABLE TO TOLERATE AN EFFECTIVE DOSE OF A HMG-COA REDUCTASE INHIBITOR DUE TO MUSCLE RELATED SIDE EFFECTS
• "A MULTI-CENTER, RANDOMIZED STUDY IN SUBJECTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPDEMIA TO ASSESS SUBJECTS' ABILITY TO ADMINISTER A FULL DOSE OF AMG 145 IN HOME-USE, USING EITHER A 3.5ML PERSONAL INJECTOR OR A PREFILLED AUTOINJECTOR/PEN."

View on source registry